An assessment of immunoreactive epidermal growth factor in urine of patients with urological diseases

Nan-Haw Chow, T. S. Tzai, P. E. Cheng, Chih-Jen Chang, J. S.N. Lin, Ming-Jer Tang

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

To examine the excretion of urinary epidermal growth factor (EGF) in urological diseases and the relationship of EGF urine levels with transitional cell carcinoma (TCC), we measured the concentration of EGF by radioimmunoassay. The series comprised patients with active TCC (n=50), others in tumor-free status (n=29) and with non-neoplastic inflammatory diseases (n=43), and normal controls (n=50). Urinary EGF values were lower in patients with urological diseases of different etiologies than in normal controls (P<0.005). Mean EGF levels of patients who had previous bladder tumor resection (n=21) were not statistically different from normal controls (P=0.2). For patients with active TCC, EGF urine levels showed a significant inverse relationship to increasing tumor grade (P=0.02). In addition, subjects who had received nephrectomy for pelvic carcinoma (n=8) showed significantly lower mean EGF values than those with intact kidneys (n=21), irrespective of sex (P<0.05). Immunostaining of EGF on non-neoplastic kidney (n=9) revealed reactivity in the distal convoluted tubules and thick ascending limbs of Henle. Our results suggest that the kidney is the major source of urinary EGF. Its excretion in urine is decreased in both inflammatory and neoplastic diseases of the urinary tract. EGF may play an important part in the biological activity of TCC. Further study is indicated to investigate the monitoring of EGF urine levels as a marker of recurrence for EGF receptor-positive TCC.

Original languageEnglish
Pages (from-to)221-225
Number of pages5
JournalUrological Research
Volume22
Issue number4
DOIs
Publication statusPublished - 1994 Jul 1

Fingerprint

Urologic Diseases
Epidermal Growth Factor
Urine
Transitional Cell Carcinoma
Kidney
Nephrectomy
Epidermal Growth Factor Receptor
Urinary Bladder Neoplasms
Radioimmunoassay
Neoplasms
Extremities

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

@article{8e7054801af1469a8594e1cd85e81d02,
title = "An assessment of immunoreactive epidermal growth factor in urine of patients with urological diseases",
abstract = "To examine the excretion of urinary epidermal growth factor (EGF) in urological diseases and the relationship of EGF urine levels with transitional cell carcinoma (TCC), we measured the concentration of EGF by radioimmunoassay. The series comprised patients with active TCC (n=50), others in tumor-free status (n=29) and with non-neoplastic inflammatory diseases (n=43), and normal controls (n=50). Urinary EGF values were lower in patients with urological diseases of different etiologies than in normal controls (P<0.005). Mean EGF levels of patients who had previous bladder tumor resection (n=21) were not statistically different from normal controls (P=0.2). For patients with active TCC, EGF urine levels showed a significant inverse relationship to increasing tumor grade (P=0.02). In addition, subjects who had received nephrectomy for pelvic carcinoma (n=8) showed significantly lower mean EGF values than those with intact kidneys (n=21), irrespective of sex (P<0.05). Immunostaining of EGF on non-neoplastic kidney (n=9) revealed reactivity in the distal convoluted tubules and thick ascending limbs of Henle. Our results suggest that the kidney is the major source of urinary EGF. Its excretion in urine is decreased in both inflammatory and neoplastic diseases of the urinary tract. EGF may play an important part in the biological activity of TCC. Further study is indicated to investigate the monitoring of EGF urine levels as a marker of recurrence for EGF receptor-positive TCC.",
author = "Nan-Haw Chow and Tzai, {T. S.} and Cheng, {P. E.} and Chih-Jen Chang and Lin, {J. S.N.} and Ming-Jer Tang",
year = "1994",
month = "7",
day = "1",
doi = "10.1007/BF00541896",
language = "English",
volume = "22",
pages = "221--225",
journal = "Urolithiasis",
issn = "2194-7228",
publisher = "Springer Verlag",
number = "4",

}

An assessment of immunoreactive epidermal growth factor in urine of patients with urological diseases. / Chow, Nan-Haw; Tzai, T. S.; Cheng, P. E.; Chang, Chih-Jen; Lin, J. S.N.; Tang, Ming-Jer.

In: Urological Research, Vol. 22, No. 4, 01.07.1994, p. 221-225.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An assessment of immunoreactive epidermal growth factor in urine of patients with urological diseases

AU - Chow, Nan-Haw

AU - Tzai, T. S.

AU - Cheng, P. E.

AU - Chang, Chih-Jen

AU - Lin, J. S.N.

AU - Tang, Ming-Jer

PY - 1994/7/1

Y1 - 1994/7/1

N2 - To examine the excretion of urinary epidermal growth factor (EGF) in urological diseases and the relationship of EGF urine levels with transitional cell carcinoma (TCC), we measured the concentration of EGF by radioimmunoassay. The series comprised patients with active TCC (n=50), others in tumor-free status (n=29) and with non-neoplastic inflammatory diseases (n=43), and normal controls (n=50). Urinary EGF values were lower in patients with urological diseases of different etiologies than in normal controls (P<0.005). Mean EGF levels of patients who had previous bladder tumor resection (n=21) were not statistically different from normal controls (P=0.2). For patients with active TCC, EGF urine levels showed a significant inverse relationship to increasing tumor grade (P=0.02). In addition, subjects who had received nephrectomy for pelvic carcinoma (n=8) showed significantly lower mean EGF values than those with intact kidneys (n=21), irrespective of sex (P<0.05). Immunostaining of EGF on non-neoplastic kidney (n=9) revealed reactivity in the distal convoluted tubules and thick ascending limbs of Henle. Our results suggest that the kidney is the major source of urinary EGF. Its excretion in urine is decreased in both inflammatory and neoplastic diseases of the urinary tract. EGF may play an important part in the biological activity of TCC. Further study is indicated to investigate the monitoring of EGF urine levels as a marker of recurrence for EGF receptor-positive TCC.

AB - To examine the excretion of urinary epidermal growth factor (EGF) in urological diseases and the relationship of EGF urine levels with transitional cell carcinoma (TCC), we measured the concentration of EGF by radioimmunoassay. The series comprised patients with active TCC (n=50), others in tumor-free status (n=29) and with non-neoplastic inflammatory diseases (n=43), and normal controls (n=50). Urinary EGF values were lower in patients with urological diseases of different etiologies than in normal controls (P<0.005). Mean EGF levels of patients who had previous bladder tumor resection (n=21) were not statistically different from normal controls (P=0.2). For patients with active TCC, EGF urine levels showed a significant inverse relationship to increasing tumor grade (P=0.02). In addition, subjects who had received nephrectomy for pelvic carcinoma (n=8) showed significantly lower mean EGF values than those with intact kidneys (n=21), irrespective of sex (P<0.05). Immunostaining of EGF on non-neoplastic kidney (n=9) revealed reactivity in the distal convoluted tubules and thick ascending limbs of Henle. Our results suggest that the kidney is the major source of urinary EGF. Its excretion in urine is decreased in both inflammatory and neoplastic diseases of the urinary tract. EGF may play an important part in the biological activity of TCC. Further study is indicated to investigate the monitoring of EGF urine levels as a marker of recurrence for EGF receptor-positive TCC.

UR - http://www.scopus.com/inward/record.url?scp=0028151025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028151025&partnerID=8YFLogxK

U2 - 10.1007/BF00541896

DO - 10.1007/BF00541896

M3 - Article

VL - 22

SP - 221

EP - 225

JO - Urolithiasis

JF - Urolithiasis

SN - 2194-7228

IS - 4

ER -